Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
T | 0.700 | GeneticVariation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||
|
C | 0.700 | GeneticVariation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||
|
C | 0.700 | GeneticVariation | CLINVAR | This scenario of Q252H-associated TKI resistance with rapid BC transformation has not been previously documented in e19a2 BCR-ABL1 CML. | 24109527 | 2013 |
|||
|
C | 0.700 | GeneticVariation | CLINVAR | Mutations in ABL kinase domain are associated with inferior progression-free survival. | 20367437 | 2010 |
|||
|
C | 0.700 | GeneticVariation | CLINVAR | Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. | 15256422 | 2004 |
|||
|
T | 0.700 | GeneticVariation | CLINVAR | Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. | 15256422 | 2004 |
|||
|
C | 0.700 | GeneticVariation | CLINVAR | Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. | 12623848 | 2003 |
|||
|
T | 0.700 | GeneticVariation | CLINVAR | Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. | 12623848 | 2003 |
|||
|
C | 0.700 | GeneticVariation | CLINVAR | Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. | 12399961 | 2002 |